N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to determine the regulatory role of N-acetyl- l-cysteine (NAC), an antioxidant, in interleukin 17 (IL-17)-induced osteoclast differentiation in rheumatoid arthritis (RA). Methods: After RA synovial fibroblasts were stimulated by IL-17, the expression and production of receptor activator of nuclear factor κ-B ligand (RANKL) was determined by real-time polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA). Osteoclastogenesis was also determined after co-cultures of IL-17-stimulated RA synovial fibroblasts, Th17 cells and various concentrations of NAC with monocytes. After human peripheral CD4+ T cells were cultured with NAC under Th17 condition, IL-17, interferon γ, IL-4, Foxp3, RANKL, and IL-2 expression and production was determined by flow cytometry or ELISA. Results: When RA synovial fibroblasts were stimulated by IL-17, IL-17 stimulated the production of RANKL, and NAC reduced the IL-17-induced RANKL production in a dose-dependent manner. NAC decreased IL-17-activated phosphorylation of mammalian target of rapamycin, c-Jun N-terminal kinase, and inhibitor of κB. When human peripheral blood CD14+ monocytes were cultured with macrophage colony-stimulating factor and IL-17 or RANKL, osteoclasts were differentiated, and NAC reduced the osteoclastogenesis. After human peripheral CD4+ T cells were co-cultured with IL-17-pretreated RA synovial fibroblasts or Th17 cells, NAC reduced their osteoclastogenesis. Under Th17 polarizing condition, NAC decreased Th17 cell differentiation and IL-17 and RANKL production. Conclusions: NAC inhibits the IL-17-induced RANKL production in RA synovial fibroblasts and IL-17-induced osteoclast differentiation. NAC also reduced Th17 polarization. NAC could be a supplementary therapeutic option for inflammatory and bony destructive processes in RA.
Abstract
Background/Aims: This study aimed to determine the regulatory role of N-acetyl- l-cysteine (NAC), an antioxidant, in interleukin 17 (IL-17)-induced osteoclast differentiation in rheumatoid arthritis (RA). Methods: After RA synovial fibroblasts were stimulated by IL-17, the expression and production of receptor activator of nuclear factor κ-B ligand (RANKL) was determined by real-time polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA). Osteoclastogenesis was also determined after co-cultures of IL-17-stimulated RA synovial fibroblasts, Th17 cells and various concentrations of NAC with monocytes. After human peripheral CD4+ T cells were cultured with NAC under Th17 condition, IL-17, interferon γ, IL-4, Foxp3, RANKL, and IL-2 expression and production was determined by flow cytometry or ELISA. Results: When RA synovial fibroblasts were stimulated by IL-17, IL-17 stimulated the production of RANKL, and NAC reduced the IL-17-induced RANKL production in a dose-dependent manner. NAC decreased IL-17-activated phosphorylation of mammalian target of rapamycin, c-Jun N-terminal kinase, and inhibitor of κB. When human peripheral blood CD14+ monocytes were cultured with macrophage colony-stimulating factor and IL-17 or RANKL, osteoclasts were differentiated, and NAC reduced the osteoclastogenesis. After human peripheral CD4+ T cells were co-cultured with IL-17-pretreated RA synovial fibroblasts or Th17 cells, NAC reduced their osteoclastogenesis. Under Th17 polarizing condition, NAC decreased Th17 cell differentiation and IL-17 and RANKL production. Conclusions: NAC inhibits the IL-17-induced RANKL production in RA synovial fibroblasts and IL-17-induced osteoclast differentiation. NAC also reduced Th17 polarization. NAC could be a supplementary therapeutic option for inflammatory and bony destructive processes in RA.
참고문헌 (37)
- Harris ED Jr, "Rheumatoid arthritis : pathophysiology and implications for therapy", N Engl J Med, 322, pp.1277~1289 (1990)
- Molenaar ET, "Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission", Arthritis Rheum, 50, pp.36~42 (2004)
- Gravallese EM, "Bone destruction in arthritis", Ann Rheum Dis, (61 Suppl 2), pp.ii84~ii86 (2002)
- Harrington LE, "Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages", Nat Immunol, 6, pp.1123~1132 (2005)
- Tesmer LA, "Th17 cells in human disease", Immunol Rev, 223, pp.87~113 (2008)
- Takayanagi H, "Osteoimmunology : shared mechanisms and crosstalk between the immune and bone systems", Nat Rev Immunol, 7, pp.292~304 (2007)
- Jovanovic DV, "IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages", J Immunol, 160, pp.3513~3521 (1998)
- Adamopoulos IE, "Synovial fluid macrophages are capable of osteoclast formation and resorption", J Pathol, 208, pp.35~43 (2006)
- Rosen CJ, "Mechanisms of disease: is osteoporosis the obesity of bone?", Nat Clin Pract Rheumatol, 2, pp.35~43 (2006)
- Pfeilschifter J, "Changes in proinflammatory cytokine activity after menopause", Endocr Rev, 23, pp.90~119 (2002)
- Lean JM, "Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation", Endocrinology, 146, pp.728~735 (2005)
- Lee NK, "A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation", Blood, 106, pp.852~859 (2005)
- Lean JM, "A crucial role for thiol antioxidants in estrogen-deficiency bone loss", J Clin Invest, 112, pp.915~923 (2003)
- Chen JR, "A role for ethanol-induced oxidative stress in controlling lineage commitment of mesenchymal stromal cells through inhibition of Wnt", beta-catenin signaling, 2010, pp.25, 1117~1127
- Hsu HY, "Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression", J Biol Chem, 277, pp.22131~22139 (2002)
- Kim KW, "Up-regulation of stromal cell-derived factor 1(CXCL12)production in rheumatoid synovial fibroblasts through interactions with T lymphocytes : role of interleukin-17 and CD40L-CD40interaction", Arthritis Rheum, 56, pp.1076~1086 (2007)
- 문수진, "Engagement of Toll-Like Receptor 3 Induces Vascular Endothelial Growth Factor and Interleukin-8 in Human Rheumatoid Synovial Fibroblasts", The Korean Journal of Internal Medicine, 25(4), pp.429~435 (2010), 대한내과학회
- Brentano F, "RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3", Arthritis Rheum, 52, pp.2656~2665 (2005)
- Wu Y, "Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis", Arthritis Rheum, 52, pp.3257~3268 (2005)
- Kong YY, "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis", Nature, 397, pp.315~323 (1999)
- Yasuda H, "Osteoclast differentiation factor is a ligand for osteoprotegerin", osteoclastogenesis-inhibitory factor and is identical to TRANCE, Proc Natl Acad Sci U S A, pp.1998, 95[DOI]
- Fujikawa Y, "The effect of macrophage-colony stimulating factor and other humoral factors(interleukin-1, -3, -6, and-11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor)on human osteoclast formation from circulating cells", Bone, 28, pp.261~267 (2001)
- Kim KW, "Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis", Am J Pathol, 185, pp.3011~3024 (2015)
- Garrett IR, "Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo", J Clin Invest, 85, pp.632~639 (1990)
- Nakamura I, "Regulation of osteoclast function", Mod Rheumatol, 22, pp.167~177 (2012)
- Gronthos S, "The role of the chemokine CXCL12 in osteoclastogenesis", Trends Endocrinol Metab, 18, pp.108~113 (2007)
- Kim HR, "The effect of vascular endothelial growth factor on osteoclastogenesis in rheumatoid arthritis", PLoS One, 10, pp.e0124909~ (2015)
- Gokcimen A, "Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity", Hum Exp Toxicol, 26, pp.519~525 (2007)
- Zafarullah M, "Molecular mechanisms of N-acetylcysteine actions", Cell Mol Life Sci, 60, pp.6~20 (2003)
- Dickey DT, "Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models", Cancer Chemother Pharmacol, 62, pp.235~241 (2008)
- Koenders MI, "Secukinumab for rheumatology : development and its potential place in therapy", Drug Des Devel Ther, 10, pp.2069~2080 (2016)
- Genovese MC, "Efficacy and safety of secukinumab in patients with rheumatoid arthritis : a phase II, dose-finding, double-blind, randomised, placebo controlled study", Ann Rheum Dis, 72, pp.863~869 (2013)
- 송관규, "Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials", The Korean Journal of Internal Medicine, 29(5), pp.656~663 (2014), 대한내과학회[DOI]
- Saxena A, "Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent", Arthritis Rheum, 63, pp.1465~1466 (2011)
- Cejka D, "Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis", Arthritis Rheum, 62, pp.2294~2302 (2010)
- Sakurada S, "Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin", Int Immunol, 8, pp.1483~1493 (1996)
- Saliou C, "Antioxidants modulate acute solar ultraviolet radiation-induced NF-kappa-B activation in a human keratinocyte cell line", Free Radic Biol Med, 26, pp.174~183 (1999)